Clinical Trial

Bosentan in the Treatment of Giant Cell Arteritis

Study acronym: BOSICART
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine whether a treatment with 3 months of bosentan associated to standard therapy might be superior to glucocorticoids alone in term of failure free survival at 12 months
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-25; most recent amendment 2026-04-30.
Trial Details
NCT Number NCT06957002
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Collaborators: URC-CIC Paris Descartes Necker Cochin
Conditions Giant Cell Arteritis (GCA)
Enrollment 40 participants
Start Date 2026-06
Primary Completion 2029-06 (estimated)
Study Completion 2030-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-06